Lab Reagents
Cytomegalovirus Antibody Laboratories manufactures the cytomegalovirus cmv/hhv5 igg jellemzői magyarul reagents distributed by Genprice. The Cytomegalovirus Cmv/Hhv5 Igg Jellemzői Magyarul reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact cytomegalovirus Antibody. Other Cytomegalovirus products are available in stock. Specificity: Cytomegalovirus Category: Cmv/Hhv5 Group: Igg Jellemzői
Igg Jellemzői information
Virus Cytomegalovirus (CMV) Protein |
abx670257-1ml |
Abbexa |
1 ml |
EUR 493.2 |
|
Cytomegalovirus Antibody / CMV / PP65 |
V2332-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease. |
Cytomegalovirus Antibody / CMV / PP65 |
V2332-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease. |
Cytomegalovirus Antibody / CMV / PP65 |
V2332SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease. |
Cytomegalovirus Antibody / CMV / PP65 |
V2333-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease. |
Cytomegalovirus Antibody / CMV / PP65 |
V2333-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease. |
Cytomegalovirus Antibody / CMV / PP65 |
V2333SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease. |
Cytomegalovirus (CMV) Chimeric 1 Protein |
abx061513-1mg |
Abbexa |
1 mg |
EUR 1796.4 |
|
Cytomegalovirus gH (CMV gH) Antibody |
abx415688-01mg |
Abbexa |
0.1 mg |
EUR 777.6 |
|
Cytomegalovirus (CMV) IgM ELISA Kit |
K4151-100 |
Biovision |
each |
EUR 646.8 |
Human Cytomegalovirus IgG / IgM, Toxoplasma IgG / IgM, Rubella IgG Rapid Test Kit |
abx092078-20tests |
Abbexa |
20 tests |
EUR 410.4 |
|
CMV (Cytomegalovirus Antibody IgM) ELISA test |
29 |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of CMV (Cytomegalovirus Antibody IgM) |
Virus Cytomegalovirus Antigen (CMV-Ag) Protein |
abx670278-1mg |
Abbexa |
1 mg |
EUR 1045.2 |
|
Cytomegalovirus Early Antigen (CMV-EA) Antibody |
abx411287-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
CMV control lentivirus (Hygro) |
CMV-Null-Hygro |
GenTarget |
1 x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the hygromycin selection under RSV promoter. |
CMV control lentivirus (Zeo) |
CMV-Null-Zeo |
GenTarget |
1 x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the Zeocin selection under RSV promoter. |
CMV Control lentiviral particles (Bsd) |
CMV-Null-Bsd |
GenTarget |
1 x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the blasticidin marker under RSV promoter. |